<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654975</url>
  </required_header>
  <id_info>
    <org_study_id>S64060</org_study_id>
    <nct_id>NCT04654975</nct_id>
  </id_info>
  <brief_title>Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)</brief_title>
  <acronym>METABREC</acronym>
  <official_title>Risk Factors and Treatment Options for Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer: a Multicentric Retrospective Cohort Study (METABREC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite&#xD;
      this treatment, patients can suffer from locoregional or distant metastatic disease and only&#xD;
      a very selected group of patients can be cured: mostly those with recurrence in one single&#xD;
      organ.&#xD;
&#xD;
      Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on&#xD;
      survival. Agressive treatment is often moren difficult for brain metastases compared to other&#xD;
      metastases and some risk factors have been identified earlier.&#xD;
&#xD;
      There is an impression that the incidence of brain metastases in esophageal cancer patients&#xD;
      has increased since the introduction of neoadjuvant treatment schemes. However, this is not&#xD;
      clear yet. A potential explanation could be that chemotherapy disturbs the&#xD;
      blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain.&#xD;
&#xD;
      The purpose of this study is to retrospectively analyze the incidence and potential risk&#xD;
      factors of brain metastases in patients who underwent esophagectomy for esophageal cancer.&#xD;
      Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio&#xD;
      for brain metastases (comparison between primary surgery and neoadjuvant treatment followed&#xD;
      by surgery), time to recurrence and risk factors, number and characteristics of the brain&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Odds ratio (OR) for brain metastasis</measure>
    <time_frame>1 January 2000 - 1 March 2020</time_frame>
    <description>Odds ratio (OR) for brain metastasis compared between primary surgery and neoadjuvant treatment plus surgery, OR for different neoadjuvant treatment regimes, corrected for gender and tumor factors (histology, stage, tumor differentiation,…) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 January 2000 - 1 March 2020</time_frame>
    <description>Overall survival after diagnosis of brain metastases stratified for treatment regimens applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>1 January 2000 - 1 March 2020</time_frame>
    <description>Time to recurrence, between incidence date of esophageal cancer and diagnosis of brainM+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for single site brain metastasis</measure>
    <time_frame>1 January 2000 - 1 March 2020</time_frame>
    <description>such as different neoadjuvant treatment regimes, age, gender,and tumor factors (histology, stage, tumor differentiation,…)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of brain metastases</measure>
    <time_frame>1 January 2000 - 1 March 2020</time_frame>
    <description>Number of brain metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of brain metastases</measure>
    <time_frame>1 January 2000 - 1 March 2020</time_frame>
    <description>solitary/multiple; location /side in the brain; treatment) and the effects on 'OS after recurrence' (e.g. is there a significant survival benefit in patients with brainM+ if they are treated with brain-surgery and/or stereotactic radiotherapy compared to non-treated BrainM+ or palliative treatments of brainM+</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Esophagectomy</condition>
  <condition>Brain Metastases</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Esophagectomy for esophageal cancer</intervention_name>
    <description>Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31&#xD;
        december 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and&#xD;
             31 december 2019&#xD;
&#xD;
          -  All types of neoadjuvant treatment followed by surgery, primary surgery or salvage&#xD;
             surgery.&#xD;
&#xD;
          -  Adenocarcinoma or squamous cell carcinoma histology&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other histology type than adenocarcinoma or squamous cell carcinoma&#xD;
&#xD;
          -  Hypopharyngeal carcinoma extending to the esophagus (requiring total&#xD;
             laryngo-pharyngo-esophagectomy)&#xD;
&#xD;
          -  Early esophageal carcinoma (cT IS-1a N0 M0)&#xD;
&#xD;
          -  palliative esophagectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lieven P Depypere, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lieven P Depypere, PhD</last_name>
    <phone>+32 16 346820</phone>
    <email>lieven.depypere@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johnny Moons, Msc</last_name>
    <phone>+32 16 346820</phone>
    <email>johnny.moons@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Abraham</last_name>
    </contact>
    <investigator>
      <last_name>Wayne Hofstetter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inge Vandenbroucke</last_name>
    </contact>
    <investigator>
      <last_name>Elke Van Daele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier régional Universitaire de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien Degisors</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume Piessen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Noel E Donlon</last_name>
    </contact>
    <investigator>
      <last_name>John Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daan Voeten</last_name>
    </contact>
    <investigator>
      <last_name>Mark Van Berge Henegouwen, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland MC</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie Van Den Bosch, MD</last_name>
    </contact>
    <investigator>
      <last_name>Meindert Sosef, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>x gao</last_name>
    </contact>
    <investigator>
      <last_name>Bas Wijnhoven, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biying Huang</last_name>
    </contact>
    <investigator>
      <last_name>Magnus Nilsson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

